Specify a stock or a cryptocurrency in the search bar to get a summary
Gamida Cell Ltd
GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel. Address: 5 Nahum Heftsadie Street, Jerusalem, Israel, 91340
Analytics
WallStreet Target Price
4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GMDA
Dividend Analytics GMDA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GMDA
Stock Valuation GMDA
Financials GMDA
Results | 2019 | Dynamics |